{"id":"carbamazepin","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Dizziness","drugRate":"","severity":"common","organSystem":""},{"effect":"Drowsiness","drugRate":"","severity":"common","organSystem":""},{"effect":"Unsteadiness","drugRate":"","severity":"common","organSystem":""},{"effect":"Nausea","drugRate":"","severity":"common","organSystem":""},{"effect":"Vomiting","drugRate":"","severity":"common","organSystem":""},{"effect":"Headache","drugRate":"","severity":"common","organSystem":""},{"effect":"Fatigue","drugRate":"","severity":"common","organSystem":""},{"effect":"Blurred vision","drugRate":"","severity":"common","organSystem":""},{"effect":"Disturbances of coordination","drugRate":"","severity":"common","organSystem":""},{"effect":"Confusion","drugRate":"","severity":"common","organSystem":""},{"effect":"Gastric distress","drugRate":"","severity":"common","organSystem":""},{"effect":"Abdominal pain","drugRate":"","severity":"common","organSystem":""},{"effect":"Diarrhea","drugRate":"","severity":"common","organSystem":""},{"effect":"Constipation","drugRate":"","severity":"common","organSystem":""},{"effect":"Anorexia","drugRate":"","severity":"common","organSystem":""},{"effect":"Dryness of mouth and pharynx","drugRate":"","severity":"common","organSystem":""},{"effect":"Nystagmus","drugRate":"","severity":"common","organSystem":""},{"effect":"Transient diplopia","drugRate":"","severity":"common","organSystem":""},{"effect":"Urinary frequency","drugRate":"","severity":"common","organSystem":""},{"effect":"Rashes","drugRate":"","severity":"common","organSystem":""}],"contraindications":["Absence seizure","Acute intermittent porphyria","Acute nephropathy","Agranulocytosis","Anemia","Aplastic anemia","Bone marrow depression","Carbamazepine Toxicity","Chronic heart failure","Complete atrioventricular block","Conduction disorder of the heart","Depressive disorder","Disease of liver","Disorder of coronary artery","Glaucoma","HLA-B 1502 Positive Status","Hypercholesterolemia","Hypertensive disorder","Hyponatremia","Impaired renal function disorder","Kidney disease","Mood swings","Neutropenic disorder","Non-infective meningitis","Ocular hypertension","Pancytopenia","Pregnancy, function","Retention of urine","Suicidal thoughts","Syndrome of inappropriate vasopressin secretion","Thrombocytopenic disorder"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Aplastic anemia","drugRate":"","severity":"serious"},{"effect":"Stevens-Johnson Syndrome (SJS)","drugRate":"","severity":"serious"},{"effect":"Toxic Epidermal Necrolysis (TEN)","drugRate":"","severity":"serious"},{"effect":"Agranulocytosis","drugRate":"","severity":"serious"},{"effect":"Hepatic failure","drugRate":"","severity":"serious"},{"effect":"Congestive heart failure","drugRate":"","severity":"serious"},{"effect":"Myocardial infarction","drugRate":"","severity":"serious"},{"effect":"Pulmonary embolism","drugRate":"","severity":"serious"},{"effect":"Neuroleptic malignant syndrome","drugRate":"","severity":"serious"},{"effect":"Pancreatitis","drugRate":"","severity":"serious"}]},"trials":[],"_chembl":null,"aliases":["tegretol","bamgetol"],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Carbamazepin","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T02:23:03.305344+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T02:23:09.567419+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Carbamazepin","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T02:23:09.932006+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Sodium channel alpha subunit blocker","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:23:11.003681+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL108/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:23:10.655192+00:00"}},"offLabel":[],"timeline":[],"_dailymed":{"setId":"32dc301e-881d-47b0-ad16-f9ff31d19324","title":"CARBAMAZEPINE TABLET [PREFERRED PHARMACEUTICALS INC.]"},"ecosystem":[],"mechanism":{"target":"Frizzled-8, Nuclear receptor subfamily 1 group I member 2, Neuronal acetylcholine receptor; alpha2/beta4"},"_scrapedAt":"2026-03-28T00:29:47.196Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:23:12.234559+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Bipolar affective disorder, current episode manic","diseaseId":"bipolar-affective-disorder-current-episode-manic","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Bipolar disorder in remission","diseaseId":"bipolar-disorder-in-remission","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Epilepsy","diseaseId":"epilepsy","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Epilepsy characterized by intractable complex partial seizures","diseaseId":"epilepsy-characterized-by-intractable-complex-partial-seizures","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Glossopharyngeal neuralgia","diseaseId":"glossopharyngeal-neuralgia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Lennox-Gastaut syndrome","diseaseId":"lennox-gastaut-syndrome","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Localization-related epilepsy","diseaseId":"localization-related-epilepsy","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Mixed Epilepsy","diseaseId":"mixed-epilepsy","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Mixed bipolar I disorder","diseaseId":"mixed-bipolar-i-disorder","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Simple partial seizure","diseaseId":"simple-partial-seizure","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Tonic-clonic epilepsy","diseaseId":"tonic-clonic-epilepsy","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Tonic-clonic seizure","diseaseId":"tonic-clonic-seizure","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Trigeminal neuralgia","diseaseId":"trigeminal-neuralgia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07198035","phase":"PHASE1","title":"A Study to Learn if Multiple Doses of the Study Medicine Called Carbamazepine Changes How the Body Processes the Other Study Medicine PF-07248144","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-09-18","conditions":"Healthy Adults","enrollment":12},{"nctId":"NCT04923659","phase":"EARLY_PHASE1","title":"Pharmacological Mechanisms of Low-intensity Focused Ultrasound for Motor Cortex Neuroplasticity","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2021-05-25","conditions":"Low Intensity Focussed Ultrasound","enrollment":20},{"nctId":"NCT06633419","phase":"PHASE1","title":"A Drug-Drug Interaction Study of Carbamazepine and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-012)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-12-18","conditions":"Healthy","enrollment":14},{"nctId":"NCT05552196","phase":"PHASE1","title":"A Study of Ponesimod in Healthy Adult Participants","status":"COMPLETED","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2022-10-18","conditions":"Healthy","enrollment":28},{"nctId":"NCT06751017","phase":"PHASE1","title":"A Drug-drug Interaction Study of S-892216 Coadministered With Carbamazepime to Healthy Adult Participants","status":"COMPLETED","sponsor":"Shionogi","startDate":"2024-12-17","conditions":"COVID-19","enrollment":16},{"nctId":"NCT06849219","phase":"PHASE4","title":"Comparison of Oxcarbazepine Versus Carbamazepine in the Management of Trigeminal Neuralgia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jinnah Postgraduate Medical Centre","startDate":"2024-09-21","conditions":"Trigeminal Neuralgia","enrollment":122},{"nctId":"NCT05965219","phase":"PHASE1","title":"A Trial to Evaluate the Effects of Itraconazole and Carbamazepine on the Pharmacokinetics of Emraclidine and of Emraclidine on the Pharmacokinetics of Metformin in Healthy Adult Participants","status":"COMPLETED","sponsor":"Cerevel Therapeutics, LLC","startDate":"2023-08-15","conditions":"Healthy Volunteers","enrollment":60},{"nctId":"NCT02893371","phase":"","title":"Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies","status":"TERMINATED","sponsor":"University of New Mexico","startDate":"2016-09","conditions":"Bipolar Disorder","enrollment":1037352},{"nctId":"NCT06005688","phase":"PHASE1","title":"A Study to Understand the Effects of Carbamazepine on How Vepdegestrant is Processed in Healthy Participants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-08-18","conditions":"Healthy Participants","enrollment":12},{"nctId":"NCT05748236","phase":"PHASE4","title":"The Efficacy and Safety of Lamotrigine Versus Carbamazepine in Focal Epilepsy","status":"UNKNOWN","sponsor":"Dhaka Medical College","startDate":"2022-11-01","conditions":"Focal Epilepsy","enrollment":70},{"nctId":"NCT05833399","phase":"","title":"Correlation of Genetic Variations With Clinical Response in Substance Use Disorder","status":"UNKNOWN","sponsor":"Alexandria University","startDate":"2022-11-28","conditions":"Substance Use Disorders, Substance Dependence","enrollment":200},{"nctId":"NCT02623504","phase":"PHASE4","title":"DB/Maintenance of Equetro (Carbamazepine) in Children With Acute Manic or Mixed Bipolar 1 Disorder","status":"TERMINATED","sponsor":"Validus Pharmaceuticals","startDate":"2016-10-24","conditions":"Bipolar Disorder","enrollment":17},{"nctId":"NCT05697614","phase":"PHASE4","title":"The Benefit and Safety of Older Generation Anti-Epileptic Drugs (AEDs) in Drug-Resistant Epilepsy Children","status":"UNKNOWN","sponsor":"Dr Cipto Mangunkusumo General Hospital","startDate":"2023-03-01","conditions":"Drug Resistant Epilepsy","enrollment":100},{"nctId":"NCT05635071","phase":"PHASE2, PHASE3","title":"Prospective Clinical Study of Nintedanib to Inhibit Endometrial Fibrosis to Prevent Recurrence of Uterine Adhesions","status":"UNKNOWN","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2023-12-01","conditions":"Uterine Adhesions","enrollment":90},{"nctId":"NCT00621751","phase":"NA","title":"Carbamazepine for the Treatment of Chronic Post-Traumatic Brain Injury Irritability and Aggression","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2008-02","conditions":"Traumatic Brain Injury","enrollment":70},{"nctId":"NCT01379469","phase":"PHASE2","title":"Carbamazepine in Severe Liver Disease Due to Alpha-1 Antitrypsin Deficiency","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2012-01","conditions":"Alpha-1-antitrypsin Deficiency, Liver Cirrhosis","enrollment":20},{"nctId":"NCT04783753","phase":"PHASE1","title":"Drug-Drug Interaction Study Between EDP-514, Itraconazole, Carbamazepine, and Quinidine in Healthy Subjects","status":"COMPLETED","sponsor":"Enanta Pharmaceuticals, Inc","startDate":"2020-11-05","conditions":"Hepatitis B","enrollment":72},{"nctId":"NCT01243177","phase":"PHASE3","title":"Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older","status":"COMPLETED","sponsor":"UCB BIOSCIENCES GmbH","startDate":"2011-04","conditions":"Epilepsy, Monotherapy","enrollment":888},{"nctId":"NCT02870283","phase":"PHASE4","title":"Cost- Effectiveness and Quality of Life Assessment in Mood Disorder","status":"COMPLETED","sponsor":"Federal University of Rio Grande do Sul","startDate":"2010-05","conditions":"Bipolar Disorder","enrollment":107},{"nctId":"NCT02912364","phase":"PHASE4","title":"Comparison of the Cognitive and Behavioral Effects of Eslicarbazepine Acetate and Carbamazepine in Healthy Adults","status":"COMPLETED","sponsor":"Stanford University","startDate":"2016-07","conditions":"Epilepsy","enrollment":46},{"nctId":"NCT00612235","phase":"","title":"Premenstrual Dysphoric Disorder and Antiepileptic Drugs","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2008-04","conditions":"Epilepsy","enrollment":80},{"nctId":"NCT01465997","phase":"PHASE3","title":"Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older","status":"COMPLETED","sponsor":"UCB BIOSCIENCES GmbH","startDate":"2012-05","conditions":"Epilepsy, Monotherapy","enrollment":551},{"nctId":"NCT02705768","phase":"PHASE4","title":"Effect of Carbamazepine and Oxcarbazepine on Serum Neuron-specific Enolase and S100B in Focal Seizures","status":"COMPLETED","sponsor":"All India Institute of Medical Sciences, Bhubaneswar","startDate":"2016-04","conditions":"Seizures, Focal","enrollment":90},{"nctId":"NCT01954121","phase":"PHASE3","title":"Open-label, Randomized, Active-controlled Study of LEV Used as Monotherapy in Patients With Partial-Onset Seizures","status":"COMPLETED","sponsor":"UCB Pharma SA","startDate":"2013-09","conditions":"Epilepsy, Partial Seizures","enrollment":436},{"nctId":"NCT00224952","phase":"","title":"Pathogenesis of Adverse Drug Reactions","status":"COMPLETED","sponsor":"Children's Mercy Hospital Kansas City","startDate":"2002-07","conditions":"Seizures","enrollment":274},{"nctId":"NCT01089855","phase":"PHASE4","title":"Efficacy and Tolerability of Carbamazepine CR in Diabetic Neuropathy Pain","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-12","conditions":"Neuropathic Pain","enrollment":123},{"nctId":"NCT02214615","phase":"PHASE4","title":"Carbamazapine for Inherited Erythromelalgia Patients With NaV1.7 Mutations","status":"COMPLETED","sponsor":"VA Connecticut Healthcare System","startDate":"2014-04","conditions":"Erythromelalgia","enrollment":2},{"nctId":"NCT02429596","phase":"PHASE4","title":"A Trial of Generic Substitution of Antiepileptic Drugs","status":"UNKNOWN","sponsor":"IRCCS National Neurological Institute \"C. Mondino\" Foundation","startDate":"2012-05","conditions":"Epilepsy","enrollment":200},{"nctId":"NCT02208492","phase":"PHASE4","title":"The Effects on Cognitive Function of Levetiracetam (Keppra®) Compared to Carbamazepine (Tegretol®, Carmazepine®) as Monotherapy for Children With Partial Seizure; A Multicentric Randomized Controlled Study","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2011-09","conditions":"Focal Epilepsy","enrollment":75},{"nctId":"NCT02132897","phase":"PHASE1","title":"Fed Bioequivalence Study of CBZ Formulations","status":"COMPLETED","sponsor":"Center for Clinical Pharmacology Research Bdbeq S.A.","startDate":"2014-05","conditions":"Bio-equivalence Study, Fed Conditions","enrollment":20},{"nctId":"NCT00350857","phase":"PHASE4","title":"The Young Adult and Pediatric Bipolar Study","status":"COMPLETED","sponsor":"Validus Pharmaceuticals","startDate":"2006-07","conditions":"Bipolar I Disorder","enrollment":161},{"nctId":"NCT01530022","phase":"PHASE1","title":"Crossover Study of Neuropsychological Effects of Lacosamide and Carbamazepine Immediate Release in Healthy Subjects","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2012-05","conditions":"Healthy","enrollment":60},{"nctId":"NCT00610571","phase":"PHASE1","title":"Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas","status":"COMPLETED","sponsor":"Katy Peters","startDate":"2004-04","conditions":"Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma","enrollment":62},{"nctId":"NCT00612638","phase":"PHASE1","title":"Ph. I Temozolomide + O6-BG + Irinotecan in Treatment of Pts w Recurrent / Progressive Cerebral Anaplastic Gliomas","status":"COMPLETED","sponsor":"Duke University","startDate":"2005-01","conditions":"Glioblastoma, Gliosarcoma","enrollment":96},{"nctId":"NCT00734864","phase":"PHASE1","title":"Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma","status":"WITHDRAWN","sponsor":"Annick Desjardins","startDate":"2009-06","conditions":"Glioblastoma Multiforme, Gliosarcoma, Anaplastic Astrocytoma","enrollment":""},{"nctId":"NCT01390909","phase":"","title":"Clinical and Economic Burden of Uncontrolled Epilepsy: Analyses From a Medicaid Database and a Private Health Plan Database","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-05","conditions":"Epilepsy","enrollment":12386},{"nctId":"NCT00894010","phase":"PHASE2","title":"Photosensitivity Proof of Concept Trial","status":"COMPLETED","sponsor":"The Epilepsy Study Consortium","startDate":"2009-05","conditions":"Photosensitive Epilepsy","enrollment":6},{"nctId":"NCT00913107","phase":"PHASE2, PHASE3","title":"Efficacy and Safety Study of Lamotrigine to Treat Trigeminal Neuralgia","status":"COMPLETED","sponsor":"University of Malaya","startDate":"2007-09","conditions":"Trigeminal Neuralgia","enrollment":21},{"nctId":"NCT00181870","phase":"PHASE4","title":"Equetro for the Treatment of Mania in Children Ages 6-12 With Bipolar Disorder","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2005-07","conditions":"Bipolar Disorder, Mania","enrollment":33},{"nctId":"NCT00896987","phase":"PHASE4","title":"Lamotrigine Cognitive Function Study in Adult Untreated Epilepsies","status":"COMPLETED","sponsor":"Korean Epilepsy Society","startDate":"2006-05","conditions":"Epilepsy","enrollment":121},{"nctId":"NCT00203567","phase":"PHASE4","title":"Carbamazepine Extended-Release for the Treatment of Bipolar Depression","status":"COMPLETED","sponsor":"Tuscaloosa Research & Education Advancement Corporation","startDate":"2005-08","conditions":"Bipolar Depression","enrollment":25},{"nctId":"NCT00542802","phase":"PHASE3","title":"Levetiracetam Versus Carbamazepine in Post-Stroke Late Onset Crisis","status":"UNKNOWN","sponsor":"Scienze Neurologiche Ospedaliere","startDate":"2007-09","conditions":"Epileptic Seizures, Stroke","enrollment":630},{"nctId":"NCT00006395","phase":"PHASE4","title":"Drug Interaction Study of Tegretol (Carbamazepine) and St. John's Wort in Normal Volunteers","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2000-10","conditions":"Healthy","enrollment":12},{"nctId":"NCT00325286","phase":"PHASE4","title":"Open Label Study of Lithium Plus Extended-Release Carbamazepine (ERC-CBZ) for Rapid Cycling Bipolar Disorder","status":"UNKNOWN","sponsor":"Creighton University","startDate":"2006-05","conditions":"Bipolar Disorder","enrollment":20},{"nctId":"NCT00000441","phase":"PHASE4","title":"Drug Therapy for Alcohol Detoxification","status":"COMPLETED","sponsor":"National Institute on Alcohol Abuse and Alcoholism (NIAAA)","startDate":"","conditions":"Alcoholism","enrollment":""}],"_emaApprovals":[],"_faersSignals":[{"count":59,"reaction":"FATIGUE"},{"count":51,"reaction":"FALL"},{"count":38,"reaction":"DRUG INTERACTION"},{"count":38,"reaction":"HEADACHE"},{"count":36,"reaction":"SEIZURE"},{"count":33,"reaction":"PAIN IN EXTREMITY"},{"count":30,"reaction":"DIZZINESS"},{"count":29,"reaction":"DRUG INEFFECTIVE"},{"count":29,"reaction":"PAIN"},{"count":24,"reaction":"GAIT DISTURBANCE"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"chemblId":"CHEMBL108"},"formularyStatus":[],"_approvalHistory":[{"date":"20210413","type":"ORIG","sponsor":"CSPC OUYI","applicationNumber":"ANDA213311"},{"date":"20240109","type":"SUPPL","sponsor":"CSPC OUYI","applicationNumber":"ANDA213311"}],"developmentCodes":[],"ownershipHistory":[],"publicationCount":105,"therapeuticAreas":["Neuroscience"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Carbamazepin","genericName":"Carbamazepin","companyName":"Enanta Pharmaceuticals, Inc","companyId":"enanta-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Carbamazepine is a small molecule that acts as a blocker of the sodium channel alpha subunit. It is used to treat conditions such as epilepsy and bipolar disorder, and is available in controlled-release formulations.","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2021-04-13T00:00:00.000Z","mah":"CSPC OUYI","brand_name_local":null,"application_number":"ANDA213311"},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:23:12.234559+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}